Assessing the impact of hepatitis C virus coinfection on lopinavir/ritonavir trough concentrations in HIV-infected patients

European Journal of Clinical Pharmacology

Volumn 67, Issue 2, 2011, Pages 143-149

  Calza, Leonardo ^a   Mosca, Laura ^a   Pocaterra, Daria ^a   Piergentili, Benedetta ^a   Colangeli, Vincenzo ^a   Manfredi, Roberto ^a   Erario, Annalisa ^a   Grossi, Gabriele ^a   Verucchi, Gabriella ^a   Viale, Pierluigi ^a  

^a UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

Antiretroviral therapy; Chronic hepatitis C; Pharmacokinetics; Protease inhibitor; Therapeutic drug monitoring

Indexed keywords

ABACAVIR; DIDANOSINE; EMTRICITABINE; INTERFERON; LAMIVUDINE; LOPINAVIR PLUS RITONAVIR; PEGINTERFERON; RIBAVIRIN; RNA DIRECTED DNA POLYMERASE INHIBITOR; STAVUDINE; TENOFOVIR; VIRUS RNA; ZIDOVUDINE;

ADULT; ARTICLE; CONTROLLED STUDY; DIARRHEA; DRUG BLOOD LEVEL; EVENING DOSAGE; FEMALE; HEPATITIS C; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERTRIGLYCERIDEMIA; IMMUNE RESPONSE; LIVER CIRRHOSIS; MAJOR CLINICAL STUDY; MALE; MAXIMUM PLASMA CONCENTRATION; MIXED INFECTION; MORNING DOSAGE; OBSERVATIONAL STUDY; OPEN STUDY; OUTPATIENT; PRIORITY JOURNAL; STEADY STATE; TANDEM MASS SPECTROMETRY; TREATMENT DURATION; VIRUS LOAD;

ADULT; FEMALE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HIV; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HUMANS; LIVER CIRRHOSIS; MALE; MIDDLE AGED; PYRIMIDINONES; RITONAVIR; VIRAL LOAD;

EID: 79151485823     PISSN: 00316970     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00228-010-0904-4     Document Type: Article

References (20)

1. AH Mohsen, et al. 2002 Hepatitis C and HIV-1 coinfection Gut 51 601 608 1:STN:280:DC%2BD38vntlSmsw%3D%3D 10.1136/gut.51.4.601 12235089
2. Rockstroh JK, Mocroft A, Soriano V et al (2005) Influence of hepatitis C virus infection on HIV-1 disease progression and response to highly active antiretroviral therapy. J Infect Dis 192:992-1002
3. Den Brinker M, Wit FW, Wertheim-van Dillen PM, et al (2000) Hepatitis B and C virus coinfection and the risk for hepatotoxicity of highly active antiretroviral therapy in HIV-1 infection. AIDS 14:3451-3455
4. Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Department of Health and Human Services. Available at: http://www.aidsinfo.nih. gov/ContentFiles/AdultandAdolescentGL.pdf
5. van Waterschoot RA, ter Heine R, Wagenaar E et al (2010) Effects of cytochrome P450 3A (CYP3A) and the drug transporters P-glycoprotein (MDR1/ABCB1) and MRP2 (ABCC2) on the pharmacokinetics of lopinavir. Br J Pharmacol 160:1224-1233
6. FDA notifications 2005 FDA approves new Kaletra formulation AIDS Alert 20 142 143
7. Abbott Laboratories (2001) Kaletra. European summary of product characteristics. Issued: 20 Mar, 2001. Abbott Laboratories, Maidenhead
8. Back DJ, Khoo SH, Gibbons SE, Merry C (2001) The role of therapeutic drug monitoring in treatment of HIV infection. Br J Clin Pharmacol 51:301-308
9. Crommentuyn KM, Kappelhoff BS, Mulder JW, et al (2005) Population pharmacokinetics of lopinavir in combination with ritonavir in HIV-1-infected patients. Br J Clin Pharmacol 60:378-389
10. Wateba MI, Billaud E, Dailly E, Jolliet P, Raffi F (2006) Low initial trough plasma concentrations of lopinavir are associated with an impairment of virological response in an unselected cohort of HIV-1-infected patients. HIV Med 7:197-199
11. Dickinson L, Robinson L, Tjia J, et al (2005) Simultaneous determination of HIV protease inhibitors amprenavir, atazanavir, indinavir, lopinavir, nelfinavir, ritonavir and saquinavir in human plasma by high-performance liquid chromatography-tandem mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci 829:82-90
12. J Moltó A Blanco C Miranda, et al. 2007 Variability in non-nucleoside reverse transcriptase and protease inhibitors concentrations among HIV-infected adults in routine clinical practice Br J Clin Pharmacol 63 715 721 10.1111/j.1365-2125.2006.02834.x 17223856
13. Wolfe R, Carlin JB (1999) Sample-size calculation for a log-transformed outcome measure. Control Clin Trials 20:547-554
14. Peng JZ, Pulido F, Causemaker SJ, et al (2006) Pharmacokinetics of lopinavir/ritonavir in HIV/hepatitis C virus-coinfected subjects with hepatic impairment. J Clin Pharmacol 46:265-274
15. Barreiro P, RodrIguez-Novoa S, Labarga P et al (2007) Influence of liver fibrosis stage on plasma levels of antiretroviral drugs in HIV-infected patients with chronic hepatitis C. J Infect Dis 195:973-979
16. Slish J, Ma Q, Zingman BS, et al (2007) Assessing the impact of substance use and hepatitis coinfection on atazanavir and lopinavir trough concentrations in HIV-infected patients during therapeutic drug monitoring. Ther Drug Monit 29:560-565
17. Canta F, Marrone R, Bonora S, et al (2005) Pharmacokinetics and hepatotoxicity of lopinavir/ritonavir in non-cirrhotic HIV and hepatitis C virus (HCV) coinfected patients. J Antimicrob Chemother 55:280-281
18. J Moltò, et al. 2007 Lopinavir/ritonavir pharmacokinetics in HIV and hepatitis C virus coinfected patients without liver function impairment: influence of liver fibrosis Clin Pharmacokinet 46 85 92 10.2165/00003088- 200746010-00005 17201460
19. Micheli V, Regazzi M, Dickinson L, Meraviglia P, et al (2008) Lopinavir/ritonavir pharmacokinetics in HIV/HCV-coinfected patients with or without cirrhosis. Ther Drug Monit 30:306-313
20. Donnerer J, Haas BJ, Kessler HH (2008) Single-measurement therapeutic drug monitoring of the HIV/AIDS drugs abacavir, zidovudine, lamivudine, efavirenz, nevirapine, lopinavir and nelfinavir. Pharmacology 82:287-292